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Case Report
Alpha-Methylacyl-Coenzyme A Racemase-Expressing Urachal 
Adenocarcinoma of the Abdominal Wall
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Sang-Cheol Lee, Wun-Jae Kim
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Urachal adenocarcinomas are very rare and about one third of these neoplasms arise 
in urachal remnants. To demonstrate the origin of the urachal adenocarcinoma is not 
easy, but it is very important for managing patient care. We report on a 35-year-old 
man who complained of a palpable mass in the periumbilical area. The mass was in-
cidentally identified 10 days earlier. Computed tomography revealed a well-defined 
enhancing mass with internal calcification and septation abutting on the dome of the 
urinary bladder. The clinical diagnosis was urachal cancer, which seemed to invade 
the urinary bladder. Thus, we performed mass excision and partial resection of the 
bladder. Histopathologically, the mass was diagnosed as mucinous cystadenocarcinoma 
originating from urachal remnants that showed an unusual expression of alpha-meth-
ylacyl-coenzyme A racemase (AMACR). To our knowledge, this report is the first case 
of AMACR-expressing urachal adenocarcinoma arising in the abdominal wall.
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Urachal adenocarcinomas are an uncommon malignancy 
accounting for 0.17-0.34% of all bladder cancers and 20- 
39% for adenocarcinomas of the bladder [1]. Diagnosis of 
urachal adenocarcinoma often requires distinguishing it 
from primary bladder cancer and metastasis from other 
sites. Although distinction between them is important in 
clinical management, there have been few studies about 
this issue and no reliable markers have been described [2,3]. 
Alpha-methylacyl-coenzyme A racemase (AMACR) is an 
enzyme involved in β-oxidation of branched-chain fatty 
acids in mitochondria and peroxisomes, and it is frequently 
expressed in prostatic carcinomas and occasionally in oth-
er types of carcinomas [4-6]. We report a case of urachal ad-
enocarcinoma arising in the abdominal wall with ex-
pression of AMACR and review the related literature.
CASE REPORT
A 35-year-old man had presented with a periumbilical 
mass 10 days earlier. On physical examination, the abdo-
men was fully protruded, and the mass was palpable. 
Laboratory tests of blood and urinary analysis were within 
normal limits. Computed tomography (CT) revealed a 
well-circumscribed, multilocular cystic mass along the 
midline of the lower abdomen, measuring 9 cm in its max-
imum diameter. The mass was located adjacent to the dome 
of the urinary bladder. Punctate, annular, curvilinear and 
peripheral calcifications were demonstrated in the cystic 
wall and septa (Fig. 1). The anterior portion of this mass 
was surrounded by the areolar fat layer of the prevesical 
space of Retzius and this location strongly suggested its 
urachal origin. There was no evidence of any other solid or-
gan mass or metastatic lesion by CT. 
　In cystoscopic findings, there were no abnormal mucosal 
lesions. Laparotomy was carried out, and an about 10 cm 
sized hard mass was identified. The mass was cystic, encap-
sulated and extraperitoneally located in the prevesical 
space, and it was attached to the dome of the urinary blad-
der and continued to the umbilicus with a urachal remnant. 
The cystic mass and urachal remnant were resected and Korean J Urol 2010;51:498-500
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FIG. 1. Computed tomography through the lower abdomen 
showing a midline-lying, well circumscribed multilocular calcified
cystic mass (arrow).
FIG. 2. Photomicrograph of the wall of the multilocular cystic mass
shows mucin lakes by immunohistochemistry (H&E, x100).
FIG. 3. The lining tumor cells are stratified columnar epithelium
that shows oval to round nuclei and abundant cytoplasm by 
immunohistochemistry (H&E, x400).
FIG. 4. The tumor cells express alpha-methylacyl-coenzyme A 
racemase by immunohistochemistry (H&E, x400).
partial resection of the bladder was performed, including 
a cuff of the bladder as well. Grossly, the resected bladder 
margin and inner mucosa were clear without invasion, and 
we found no evidence of peritoneal implants or pseudomyx-
oma peritonei in the intraperitoneal space. 
　Microscopically, the tumor was composed of stratified 
columnar epithelia that lined a cyst. The tumor cells showed 
oval to round nuclei and abundant cytoplasm (Fig. 2). 
Mitotic figures were frequently identified. Acellular mucin 
dissected through the connective tissue mimicking in-
vasion, which resulted in diffuse inflammatory responses 
(Fig. 3). By immunohistochemistry, the tumor cells were 
positive for cytokeratin 7 (weak), cytokeratin 20, carci-
noembryonic antigen (CEA) and AMACR, and negative for 
prostate-specific antigen (PSA) and high molecular weight 
cytokeratin (Fig. 4). The final diagnosis was mucinous cys-
tadenocarcinoma arising in the urachal remnant of the ab-
dominal wall. The patient is alive and well with no evidence 
of recurrence clinically or radiographically at 12 months af-
ter treatment.
DISCUSSION
Urachal adenocarcinomas are rare, representing less than 
0.5% of all bladder cancers and 20-39% of primary adeno-
carcinomas of the bladder [1]. Because urachal remnant 
diseases are uncommon and manifest with nonspecific ab-
dominal or urinary signs or symptoms, a definitive presur-
gical diagnosis is not easy [7]. Urachal neoplasms follow 
variable clinical courses. Some cases are associated with 
early local invasion, so they have a poor prognosis. On the 
other hand, there are indolent cases of urachal tumours Korean J Urol 2010;51:498-500
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confined for a long time without local invasion or distant 
metastases [8]. Unfortunately, it is not easy to distinguish 
urachal adenocarcinoma from other origins of adeno-
carcinoma, but distinction between them is important in 
determining an appropriate therapy and assessing prog-
nosis. Although the normal urachus is most commonly 
lined by transitional epithelium, urachal carcinomas pre-
dominantly manifest as adenocarcinomas, which are lined 
by mucus-secreting epithelial cells resembling those of the 
colorectum, probably due to metaplasia of the urachal mu-
cosa into columnar epithelium followed by malignant 
transformation [9]. Therefore, a biologic marker for con-
firming the origin of the urachal adenocarcinoma is needed.
　Several studies have differentiated among bladder, ura-
chal, and metastatic adenocarcinoma. Torenbeek et al 
showed that CEA, PSA, OC125, and vimentin can be help-
ful in differentiating primary adenocarcinomas of the uri-
nary bladder from secondary involvement by adeno-
carcinomas originating from surrounding organs [2]. CEA 
was expressed in all urachal adenocarcinomas, 96% of co-
lonic adenocarcinomas, and only 29% of the bladder neo-
plasms. The results of CEA expression in urachal and co-
lonic carcinomas may represent the fact that the embryo-
logic origin of the urachus and colon is the same [1]. Cyto-
keratin 7 expression was expressed in 82% of adeno-
carcinomas of the bladder, and focally in 40% of urachal and 
38% of colonic adenocarcinomas. Cytokeratin 20 was ex-
pressed in more than 80% of all kinds of adenocarcinomas; 
therefore, cytokeratin 20 expression was not organ specific 
[2]. Suh et al. revealed that lack of CDX24 and villin signals 
strongly pointed to a primary bladder adenocarcinoma and 
AMACR is typically negative or weakly positive in ur-
othelial carcinoma [3]. In this case, the result of immuno-
histochemistry of the tumor was not conclusive in demon-
strating urachal adenocarcinoma. However, there was no 
clinical evidence of secondary involvement of adeno-
carcinoma from the bladder or colorectum. 
　AMACR is globally used as a reliable marker for prostate 
adenocarcinoma, but expression has also been demon-
strated in various other neoplasms [4-6]. No AMACR ex-
pression in a urachal tumor has been reported. In our case, 
the tumor cells expressed AMACR, but were PSA negative 
by immunohistochemistry. Moreover, there was no clinical 
evidence of prostate adenocarcinoma. The expression of 
AMACR in this case may be aberrant, but could be a specific 
tumor marker for urachal adenocarcinoma. Thus, as far as 
we aware, this is the first report of urachal adenocarcinoma 
originating from the abdominal wall with expression of 
AMACR. Further examinations would be needed to clarify 
if AMACR expression is specific for urachal adenocarcinoma.
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